申请人:Takeda Pharmaceutical Company Limited
公开号:EP2275411A2
公开(公告)日:2011-01-19
The present invention provides an industrially advantageous process for producing a steroid C17,20 lyase inhibitor represented by the general formula (I):
and a Reformatsky reagent in a stable form suitable for the process.
In the present invention, a compound represented by the general formula (I) is produced by reducing a specific β-hydroxy ester compound derivative or a salt thereof obtained from a specific carbonyl compound in a Reformatsky reaction in the presence of a metal hydride complex and a metal halide, and then subjecting it to a ring-closing reaction. In the above Reformatsky reaction, it is useful to use a stable solution of a compound represented by the general formula BrZnCH2COOC2H5 or a crystal of the compound which is represented by the formula (BrZnCH2COOC2H5·THF)2.
本发明提供了一种生产由通式(I)代表的类固醇 C17,20 裂解酶抑制剂的工业化有利工艺:
和一种适用于该工艺的稳定形式的 Reformatsky 试剂。
在本发明中,在金属氢化物络合物和金属卤化物存在下,通过 Reformatsky 反应还原特定 β-羟基酯化合物衍生物或由特定羰基化合物得到的其盐,然后使其进行闭环反应,即可制得通式(I)代表的化合物。在上述 Reformatsky 反应中,使用通式为 BrZnCH2COOC2H5 的化合物的稳定溶液或通式为 (BrZnCH2COOC2H5-THF)2 的化合物晶体是有用的。